Inovio's Chief Operating Officer Selected by PharmaVoice as One of the Most Inspirational Leaders in the Global Industry
September 21 2015 - 8:46PM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that
PharmaVoice, one of the leading industry publications in the life
sciences industry, has selected Dr. Niranjan Sardesai as one of its
100 most inspiring leaders of 2015. Dr. Sardesai is the Chief
Operating Officer of Inovio, a leading developer of innovative
cancer and infectious disease treatment and preventive therapies.
Those chosen for this elite group are selected for their positive
contributions as leaders who think differently, address the big
challenges facing the industry, and lead teams through inspiration.
These leaders will gather in New York City on September 17, 2015
for a celebration of their selection.
Dr. Sardesai has broad operating and consulting experience in
biotechnology and pharmaceuticals. He is responsible for leading
the company's product development programs in infectious disease
and cancer immunotherapies and delivery systems. He has secured
over $130 million in non-dilutive funding through government and
NGO grants and contracts and was Inovio's lead executive in
completing Inovio's two big pharma licensing deals with Roche and
MedImmune in the last two years.
Under his leadership the company has advanced immunotherapy
programs for cervical dysplasia, HIV, and cancers that are now in
clinical studies. He currently serves as the principal investigator
on an NIAID-funded HVDDT contract for the development of HIV
vaccines and DARPA-funded Ebola vaccine and therapeutics
programs.
Prior to Inovio, Dr. Sardesai oversaw R&D and expansion of
the oncology portfolio at Fujirebio Diagnostics, Inc. Products
developed under his leadership include new-to-the-world tests for
mesothelioma (MESOMARK™), bladder cancer and a multi-marker test
for ovarian cancer. He has authored over 40 peer-reviewed
publications, presented at over 75 invited lectures and
presentations, and filed several patents.
Dr. Sardesai said, "I am honored to be named as one of the 100
most inspiring people in the life science industry. This
prestigious recognition by PharmaVoice has been possible because of
the dedication of the Inovio people in our R&D, business
development and commercial functions."
Dr. J. Joseph Kim, President and CEO, said, "According to
PharmaVoice, their 100 Award is a means to celebrate the men and
women who provide inspiration to their peers, colleagues, and
companies through their innovative and motivation approaches to
addressing the industry's myriad challenges. We knew that about
Niranjan already, and all of us at Inovio are proud that he has
been counted among these honored few."
Established more than 10 years ago by PharmaVoice magazine, the
PharmaVoice 100 is an annual list of individuals recognized for
their positive contributions to the life science industry. Selected
from thousands of nominations, the distinguished honorees are
selected based on substantive accounts describing how they have
inspired or motivated their colleagues, peers, and even
competitors, have affected positive changes in their own
organizations, as well as give back to their communities and other
philanthropic causes.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight
against cancer and infectious diseases. We are the only
immunotherapy company that is generating T cells, in vivo, in high
quantity that are fully functional whose killing capacity
correlates with relevant clinical outcomes with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include MedImmune,
Roche, University of Pennsylvania, DARPA, GeneOne Life Science,
Drexel University, NIH, HIV Vaccines Trial Network, National Cancer
Institute, U.S. Military HIV Research Program, and University of
Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements
relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, the adequacy of our
capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, our ability
to enter into partnerships in conjunction with our research and
development programs, evaluation of potential opportunities, issues
involving product liability, issues involving patents and whether
they or licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2014,
our Form 10-Q for the quarter ended June 30, 2015, and other
regulatory filings from time to time. There can be no assurance
that any product in Inovio's pipeline will be successfully
developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market
licensed products, or that any of the forward-looking information
provided herein will be proven accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024